With a winter blood shortage looming, donate blood for a chance to win Super Bowl tickets. Here’s where to donate in Greater ...

On average, a person will make about $50-$75 per appointment. However, the amount that you can make for donating plasma will ...

A leading investment expert offers his outlook for CSL's beaten-down share price. CSL shares have dropped 1.8% today, trading at $180.67, contributing to a significant 35.8% drop for the year. The ...

These shares are starting the week in the red. Let's find out why. ASX Ltd drops almost 7% as it implements strategic commitments in response to ASIC's inquiries, requiring significant capital ...

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in ...

Forget one of one: this particular BMW 3.0 CSL is, quite literally, the very first M race car, and it’s up for sale for presumably many dollars. The very first official BMW M project was the 3.0 CSL.

Nov 18 (Reuters) - Australian biotech firm CSL (CSL.AX), opens new tab said on Tuesday it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, in a move to expand its ...

CSL Limited (OTCQX:CSLLY) (OTCQX:CMXHF), an Australian biotech focused on developing vaccines and blood-derived therapies, on Tuesday announced plans to invest approximately $1.5B in the U.S. over the ...

Australia’s largest drugmaker CSL Ltd. is committing roughly $1.5 billion to expand its US manufacturing footprint, joining a wave of pharmaceutical giants doubling down on American production. The ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company announced in August ...